Charles R. Ashby

13.8k total citations · 5 hit papers
246 papers, 10.9k citations indexed

About

Charles R. Ashby is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Oncology. According to data from OpenAlex, Charles R. Ashby has authored 246 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Molecular Biology, 102 papers in Cellular and Molecular Neuroscience and 44 papers in Oncology. Recurrent topics in Charles R. Ashby's work include Neurotransmitter Receptor Influence on Behavior (93 papers), Neuroscience and Neuropharmacology Research (62 papers) and Receptor Mechanisms and Signaling (54 papers). Charles R. Ashby is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (93 papers), Neuroscience and Neuropharmacology Research (62 papers) and Receptor Mechanisms and Signaling (54 papers). Charles R. Ashby collaborates with scholars based in United States, China and Japan. Charles R. Ashby's co-authors include Zhe‐Sheng Chen, Eliot L. Gardner, Amit K. Tiwari, Rex Y. Wang, Pranav Gupta, Rishil J. Kathawala, Christian Heidbreder, Yehuda G. Assaraf, Yoshio Minabe and Zheng‐Xiong Xi and has published in prestigious journals such as Advanced Materials, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Charles R. Ashby

242 papers receiving 10.8k citations

Hit Papers

The modulation of ABC tra... 2014 2026 2018 2022 2014 2018 2022 2023 2024 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
    2014 608 citations Rishil J. Kathawala, Pranav Gupta et al. profile →
  2. Modulating ROS to overcome multidrug resistance in cancer
    2018 545 citations Jing‐Quan Wang, Pranav Gupta et al. profile →
  3. An Enzyme‐Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis‐Based Synergistic Cancer Therapy
    2022 323 citations Yuzhi Xu, Si‐Yang Liu et al. Advanced Materials profile →
  4. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
    2023 96 citations Yuhao Xie, Jing‐Quan Wang et al. profile →
  5. Characteristic roadmap of linker governs the rational design of PROTACs
    2024 56 citations Charles R. Ashby, Ge‐Fei Hao et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles R. Ashby United States 50 5.3k 3.8k 2.4k 970 790 246 10.9k
Keqiang Ye United States 71 9.0k 1.7× 3.8k 1.0× 1.8k 0.7× 1.1k 1.2× 990 1.3× 244 17.1k
Hideaki Hara Japan 68 8.3k 1.6× 3.1k 0.8× 909 0.4× 1.1k 1.2× 661 0.8× 567 19.4k
Emanuela Esposito Italy 66 5.0k 0.9× 2.4k 0.6× 924 0.4× 2.1k 2.1× 661 0.8× 441 14.9k
Antoni Camins Spain 63 4.8k 0.9× 2.5k 0.7× 656 0.3× 1.5k 1.5× 464 0.6× 318 13.5k
Maurizio Memo Italy 54 4.6k 0.9× 3.0k 0.8× 723 0.3× 1.2k 1.2× 942 1.2× 306 10.5k
Jian Kang China 48 5.6k 1.1× 3.9k 1.0× 696 0.3× 378 0.4× 722 0.9× 204 11.1k
Carla Ghelardini Italy 58 6.0k 1.1× 2.7k 0.7× 1.2k 0.5× 2.1k 2.2× 212 0.3× 525 13.8k
Josef Krieglstein Germany 61 6.3k 1.2× 3.3k 0.9× 735 0.3× 618 0.6× 707 0.9× 307 13.3k
Jun Chen United States 80 8.7k 1.6× 2.3k 0.6× 1.1k 0.5× 641 0.7× 1.5k 1.9× 246 19.5k
Claudia Martini Italy 50 4.9k 0.9× 2.1k 0.6× 1.1k 0.5× 672 0.7× 417 0.5× 526 11.3k

Countries citing papers authored by Charles R. Ashby

Since Specialization
Citations

This map shows the geographic impact of Charles R. Ashby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles R. Ashby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles R. Ashby more than expected).

Fields of papers citing papers by Charles R. Ashby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles R. Ashby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles R. Ashby. The network helps show where Charles R. Ashby may publish in the future.

Co-authorship network of co-authors of Charles R. Ashby

This figure shows the co-authorship network connecting the top 25 collaborators of Charles R. Ashby. A scholar is included among the top collaborators of Charles R. Ashby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles R. Ashby. Charles R. Ashby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Wei‐Cheng, Xiaoyan Yang, Xiao Zhang, et al.. (2025). The Discovery of Cryptic Pockets Increases the Druggability of “Undruggable” Proteins. Medicinal Research Reviews. 45(6). 1818–1849.
2.
Kang, Xuejia, Manjusha Annaji, Rajesh Amin, et al.. (2023). Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems. Pharmaceutics. 15(6). 1567–1567. 32 indexed citations
3.
Xu, Yuzhi, Si‐Yang Liu, Leli Zeng, et al.. (2022). An Enzyme‐Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis‐Based Synergistic Cancer Therapy. Advanced Materials. 34(43). e2204733–e2204733. 323 indexed citations breakdown →
4.
Xie, Yuhao, et al.. (2022). Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer. Drugs of today. 58(8). 389–398. 5 indexed citations
5.
Li, Jia, Leli Zeng, Zheng Wang, et al.. (2021). Cycloruthenated Self‐Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers. Advanced Materials. 34(1). e2100245–e2100245. 46 indexed citations
6.
Liu, Xinyu, Jing‐Quan Wang, Charles R. Ashby, et al.. (2021). Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discovery Today. 26(5). 1284–1292. 92 indexed citations
7.
Liu, Kaisheng, Lin Gao, Xiaoshi Ma, et al.. (2020). Long non-coding RNAs regulate drug resistance in cancer. Molecular Cancer. 19(1). 54–54. 144 indexed citations
8.
Zhang, Guan-Nan, Pranav Gupta, Ming Wang, et al.. (2020). Lipid–Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. Cancers. 12(2). 498–498. 11 indexed citations
9.
Wang, Wenjing, Mengyue Zhao, Lijuan Cui, et al.. (2020). Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Molecular Cancer. 19(1). 134–134. 57 indexed citations
10.
Zeng, Leli, Jia Li, Chen Zhang, et al.. (2019). An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms. Chemical Communications. 55(26). 3833–3836. 12 indexed citations
11.
Peraman, Ramalingam, et al.. (2018). New camphor hybrids: lipophilic enhancement improves antimicrobial efficacy against drug-resistant pathogenic microbes and intestinal worms. Medicinal Chemistry Research. 27(6). 1728–1739. 7 indexed citations
12.
Karthikeyan, Chandrabose, Charles R. Ashby, Haneen Amawi, et al.. (2016). Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells. Cancer Letters. 376(1). 118–126. 28 indexed citations
13.
Kathawala, Rishil J., Kamlesh Sodani, Kang Chen, et al.. (2014). Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10–Mediated Paclitaxel Resistance: A Preclinical Study. Molecular Cancer Therapeutics. 13(3). 714–723. 34 indexed citations
14.
Ashby, Charles R., John H. Kehne, Gerd D. Bartoszyk, et al.. (2013). Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor. European Journal of Pharmacology. 714(1-3). 359–365. 24 indexed citations
15.
Tiwari, Amit K., Kamlesh Sodani, Chun‐Ling Dai, Charles R. Ashby, & Zhe‐Sheng Chen. (2011). Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy. Current Pharmaceutical Biotechnology. 12(4). 570–594. 165 indexed citations
16.
An, Xin, Amit K. Tiwari, Yibo Sun, et al.. (2010). BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leukemia Research. 34(10). 1255–1268. 232 indexed citations
17.
Dai, Chun-ling, Yong‐ju Liang, Xu Zhang, et al.. (2009). Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochemical Pharmacology. 78(4). 355–364. 25 indexed citations
18.
Dai, Chun-ling, Amit K. Tiwari, Chung‐Pu Wu, et al.. (2008). Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research. 68(19). 7905–7914. 333 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keqiang Ye Breakdown of academic impact, for papers by Hideaki Hara Breakdown of academic impact, for papers by Emanuela Esposito Breakdown of academic impact, for papers by Antoni Camins Breakdown of academic impact, for papers by Maurizio Memo Breakdown of academic impact, for papers by Jian Kang Breakdown of academic impact, for papers by Carla Ghelardini Breakdown of academic impact, for papers by Josef Krieglstein Breakdown of academic impact, for papers by Jun Chen Breakdown of academic impact, for papers by Claudia Martini
Rankless by CCL
2026